ClinicalTrials.govpublic full text
Predictive Role of MIDAS Reduction at 3 Months for Erenumab Treatment
migraine, headache, cgrp, monoclonal antibodies, pain, chronic migraine, observational
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 827009
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.